Study to Evaluate Cognitive Functioning in Remitted Depression During Treatment With Fluvoxamine

Inclusion criteria

• Diagnosis of recurrent depressive disorder at least two years prior to enrollment into the study.
• At least two severe depressive episodes with or without psychotic symptoms in the past medical history.
• Stable patient in remission since at least 4 weeks after depressive episode and not more than 6 months after depressive episode.
• Planned prescription of fluvoxamine for preventive therapy in recurrent depressive disorder.
• The subject is fluent in Russian language.
• According to Stroop test one of following points has to be met - increase of the words reading time on 10% and more or three and more mistakes done.
• Sum of Addenbrooke's Cognitive Examination total scores must be 93 or less.
• Male or female, between the ages of 18 and 65 years.
• If female, postmenopausal or birth control.

Exclusion criteria

• Diagnosis of the following concomitant psychiatric disorders: current depressive or maniac episode, bipolar affective disorder, persistent mood affective disorder (cyclothymia, dysthymia, other or unspecified persistent mood disorder), other or unspecified mood affective disorder, substance-related disorders, schizophrenia, or other psychotic disorders.
• History of a drug or alcohol disorder.
• Current treatment with fluvoxamine.
• History of depressive disorder associated with endocrine disorders.
• Pregnancy, breast-feeding female patients.
• History of any significant neurologic disease.
• Treatment with electroconvulsive therapy in the 6 months preceding the study.
• Major risk of suicide.
• Hypersensitivity to fluvoxamine.
• Use of the medications, which are known to interact with fluvoxamine.
• Have initiated psychotherapy or other therapies (such as acupuncture or hypnosis).
• Have initiated cognitive remediation therapy within 12 weeks prior enrollment or at any time during the study.